Tomasz Zemelka

Kraków Branch
Krakow, MA 31115, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study.

Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study.

Journal: Cancers

Published: July 06, 2024

Cancer care for Ukrainian refugees during the first 6 weeks of 2022 Russian invasion - An experience of a cancer reference centre in Poland.

Cancer care for Ukrainian refugees during the first 6 weeks of 2022 Russian invasion - An experience of a cancer reference centre in Poland.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 13, 2022

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population.

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population.

Journal: Cancers

Published: June 06, 2022

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Journal: Journal of clinical medicine

Published: March 23, 2022

Adjuvant combined therapy with trastuzumab in patients with HER2‑ positive breast cancer and cardiac alterations: implications for optimal cardio‑oncology care.

Adjuvant combined therapy with trastuzumab in patients with HER2‑ positive breast cancer and cardiac alterations: implications for optimal cardio‑oncology care.

Journal: Polish archives of internal medicine

Published: January 28, 2022

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.

Journal: The Journal of dermatological treatment

Published: May 31, 2021

Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

Journal: Melanoma research

Published: November 09, 2020

Real-world treatment practice in patients with advanced melanoma.

Real-world treatment practice in patients with advanced melanoma.

Journal: Contemporary oncology (Poznan, Poland)

Published: April 04, 2020

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study.

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study.

Journal: Postepy dermatologii i alergologii

Published: April 11, 2018

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

Journal: Clinical colorectal cancer

Published: August 27, 2013

Diagnostic, predictive and prognostic verification of DNA flow cytometric measurements performed at diagnosis for non-Hodgkin's lymphoma adult patients.

Diagnostic, predictive and prognostic verification of DNA flow cytometric measurements performed at diagnosis for non-Hodgkin's lymphoma adult patients.

Journal: Polish journal of pathology : official journal of the Polish Society of Pathologists

Published: April 27, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026